Hypersensitivity Pneumonitis Companies

Dec 2023Pfizer Received FDA approval for their Dupixent (dupilumab) for the treatment of adult chronic rhinosinusitis with nasal polyps (CRSwNP), which can be associated with HP.

Partnered with research institutions to explore the potential of Dupixent for treating other HP subtypes and inflammatory lung diseases.

Roche Holding AG Introduced their Actemra (tocilizumab) as a potential treatment option for HP patients with severe or refractory disease, demonstrating promising results in early clinical trials.

Collaborated with healthcare providers to expand access to Actemra for HP patients and improve treatment options.

Gilead Sciences Developed and tested their JAK inhibitor filgotinib as a potential treatment for HP in a Phase 2 trial, showing positive outcomes in symptom improvement and lung function.

Focused on expanding their portfolio of targeted therapies for various inflammatory diseases, including HP.

Siemens Healthineers Introduced their AI-powered lung imaging solutions for improved early detection and characterization of HP lesions, promoting faster diagnosis and targeted treatment planning.

Continued to invest in advanced diagnostic technologies for various respiratory diseases, including HP.

Pulmonx Corporation Developed their Zephyr Endobronchial Valve (EBV) system for lung volume reduction in severe emphysema, which can be associated with HP in some cases.

Collaborated with thoracic surgeons to expand the use of Zephyr EBV as a minimally invasive procedure for lung function improvement in HP patients with emphysema.

List of Hypersensitivity Pneumonitis Key Companies in the Market

• Novartis (Switzerland)


• Abbott (U.S.)


• AstraZeneca (U.K)


• Abbott (U.S.)


• Eli Lilly (U.S.)


• Bayer CropScience Ltd. (U.S.)


• Sun Pharma (India)


• Merck & Co. (U.S.)


• Pfizer (U.S.)